{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-000082","form_type":"8-K","ticker":"CMPX","cik":"0001738021","company_name":"Compass Therapeutics, Inc.","filed_at":"2024-01-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.351668+00:00","generated_at":"2026-06-07T03:13:23.932177+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Compass Therapeutics: CEO change to Bisker-Leib, CTX-471 CR in SCLC, $152M cash","bullets":["CEO succession: Vered Bisker-Leib appointed CEO effective Jan 9, 2024; Thomas Schuetz becomes President of R&D and Vice Chair.","Year-end 2023 cash & securities ~$152M, providing runway into mid-2026.","CTX-471: SCLC patient partial response converted to complete response; new PR in melanoma yields 27% ORR (3/11).","CTX-009: COMPANION-003 top-line data expected mid-2024; COMPANION-002 top-line data in H2 2024.","CTX-8371 IND accepted; first patient dosing expected in Q1 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-000082","json":"https://secwatch.observer/filing/0001171843-24-000082.json","markdown":"https://secwatch.observer/filing/0001171843-24-000082.md","text":"https://secwatch.observer/filing/0001171843-24-000082.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1738021/000117184324000082/0001171843-24-000082-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1738021/000117184324000082/f8k_010524.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T03:13:23.932177+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}